Evidence map›Paper›PMID 32096917›Full record

ArticleJournal of cachexia, sarcopenia and muscle2020

Indoprofen prevents muscle wasting in aged mice through activation of PDK1/AKT pathway.

Hyebeen Kim, Sung Chun Cho, Hyeon-Ju Jeong, Hye-Young Lee, Myong-Ho Jeong, Jung-Hoon Pyun, Dongryeol Ryu, MinSeok Kim, Young-Sam Lee, Minseok S Kim and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Hyebeen KimDepartment of Molecular Cell Biology, Single Cell Network Research Center, Sungkyunkwan University, Suwon, South Korea.
Sung Chun ChoWell Aging Research Center, Division of Biotechnology, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, South Korea.
Hyeon-Ju JeongDepartment of Molecular Cell Biology, Single Cell Network Research Center, Sungkyunkwan University, Suwon, South Korea.
Hye-Young LeeDepartment of Molecular Cell Biology, Single Cell Network Research Center, Sungkyunkwan University, Suwon, South Korea.
Myong-Ho JeongDepartment of Molecular Cell Biology, Single Cell Network Research Center, Sungkyunkwan University, Suwon, South Korea.
Jung-Hoon PyunDepartment of Molecular Cell Biology, Single Cell Network Research Center, Sungkyunkwan University, Suwon, South Korea.
Dongryeol RyuDepartment of Molecular Cell Biology, Single Cell Network Research Center, Sungkyunkwan University, Suwon, South Korea.
MinSeok KimSchool of Undergraduate Studies, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, South Korea.
Young-Sam LeeDepartment of New Biology, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, South Korea.
Minseok S KimDepartment of New Biology, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, South Korea.
Sang Chul ParkWell Aging Research Center, Division of Biotechnology, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, South Korea.
Yun-Il LeeWell Aging Research Center, Division of Biotechnology, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, South Korea.
Jong-Sun KangDepartment of Molecular Cell Biology, Single Cell Network Research Center, Sungkyunkwan University, Suwon, South Korea.
Daegu Gyeongbuk Institute of Science and Technology · KRSungkyunkwan University · KRSamsung Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMuscle wasting, resulting from aging or pathological conditions, leads to reduced quality of life, increased morbidity, and increased mortality. Much research effort has been focused on the development of exercise mimetics to prevent muscle atrophy and weakness. In this study, we identified indoprofen from a screen for peroxisome proliferator-activated receptor γ coactivator α (PGC-1α) inducers and report its potential as a drug for muscle wasting.

methodsThe effects of indoprofen treatment on dexamethasone-induced atrophy in mice and in 3-phosphoinositide-dependent protein kinase-1 (PDK1)-deleted C2C12 myotubes were evaluated by immunoblotting to determine the expression levels of myosin heavy chain and anabolic-related and oxidative metabolism-related proteins. Young, old, and disuse-induced muscle atrophic mice were administered indoprofen (2 mg/kg body weight) by gavage. Body weight, muscle weight, grip strength, isometric force, and muscle histology were assessed. The expression levels of muscle mass-related and function-related proteins were analysed by immunoblotting or immunostaining.

resultsIn young (3-month-old) and aged (22-month-old) mice, indoprofen treatment activated oxidative metabolism-related enzymes and led to increased muscle mass. Mechanistic analysis using animal models and muscle cells revealed that indoprofen treatment induced the sequential activation of AKT/p70S6 kinase (S6K) and AMP-activated protein kinase (AMPK), which in turn can augment protein synthesis and PGC-1α induction, respectively. Structural prediction analysis identified PDK1 as a target of indoprofen and, indeed, short-term treatment with indoprofen activated the PDK1/AKT/S6K pathway in muscle cells. Consistent with this finding, PDK1 inhibition abrogated indoprofen-induced AKT/S6K activation and hypertrophic response.

conclusionsOur findings demonstrate the effects of indoprofen in boosting skeletal muscle mass through the sequential activation of PDK1/AKT/S6K and AMPK/PGC-1α. Taken together, our results suggest that indoprofen represents a potential drug to prevent muscle wasting and weakness related to aging or muscle diseases.

Indexed as

AnimalsCyclooxygenase InhibitorsHumansIndoprofenMaleMiceMuscular AtrophyProto-Oncogene Proteins c-aktCyclooxygenase InhibitorsIndoprofenProto-Oncogene Proteins c-aktExercise mimeticHypertrophic responseIndoprofenMuscle wastingMuscle weaknessPDK1

Identifiers

PMID32096917
PMCPMC7432593
OpenAlexW3007173591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.